Severe acute respiratory syndrome (SARS) is a newly recognized illness that has spread rapidly throughout Asia, North America, and Europe. As of June 20, 2003, 8,461 people in 30 countries had developed SARS, leading to 804 deaths.[@bib1] The transmission of SARS from patients to health-care workers and other patients has been a prominent and worrisome feature of existing SARS outbreaks.[@bib2] [@bib3] The transmission of infection is thought to be through exhaled viral-laden droplets.[@bib2] [@bib3] Because many patients with SARS require supplemental oxygen administration by face mask,[@bib4] we imaged patterns of droplet dispersal with various oxygen masks to investigate the potential for possible nosocomial spread and reported our preliminary observations.

Materials and Methods {#cesec10}
=====================

After ethics board approval was obtained, the subject inhaled aerosolized 3% saline fluid droplets that were produced by an ultrasonic nebulizer (DeVilbis Ultra-Neb-99 Large-Volume Ultrasonic Nebulizer; Sunrise Medical; Somerset, PA). The breath was then held briefly (approximately 2 s), while one of three oxygen masks was fitted to the face. The subject then exhaled smoothly for \> 2 s through the mask while a series of photographs were taken. Photographs were not altered except for adjustments to brightness and contrast.

The procedure was repeated three times with each of three oxygen masks. Two of the masks had side vents for exhaled gas (a nonrebreathing mask \[Airlife Adult Oxygen Mask; Allegiance Healthcare Corp; McGaw Park, IL\] and a Venturi-type mask \[Airlife Percento~2~ Mask; Allegiance Healthcare Corp\]). The third mask had no vents. All exhaled gas exited through a single 22-mm port in the attached manifold (Hi-Ox80; Viasys; Yorba Linda, CA). The Hi-Ox80 was tested without and with a respiratory filter (Barrierbac "S"; Mallinckrodt; Mirandola, Italy) on the expiratory port. No oxygen flow was supplied to any of the masks during testing.

Results {#cesec20}
=======

A good fit was achieved with all masks: no exhaled gas was observed leaking between the edge of the mask and the face. With the nonrebreathing and Venturi-type masks, plumes of exhaled droplets could be seen exiting the side vents ([Fig 1](#fig1){ref-type="fig"} ). In the mask without vents, all exhaled vapor was directed through the exhalation port ([Fig 2](#fig2){ref-type="fig"} , *left, A*). Placing the respiratory filter on the exhalation port appeared to prevent droplets from leaving the mask ([Fig 2](#fig2){ref-type="fig"}, *right, B*). There was no increased positive pressure or increased end-tidal carbon dioxide discovered using the modified oxygen delivery system.Figure 1Subject exhaling previously inhaled saline aerosol mist while wearing nonrebreathing oxygen mask (*top, A*) and Venturi-type oxygen mask (*bottom, B*). The plume represents only exhaled breath because there was no oxygen flow into the masks.Figure 2Subject exhaling previously inhaled saline aerosol mist while wearing Hi-Ox80 oxygen mask without an added filter placed on the exhalation port (*left, A*) and with added filter placed on exhalation port (*right, B*).

Discussion {#cesec30}
==========

These preliminary observations from an ongoing study suggest the presence of a mechanism by which the method of oxygen administration can contribute to the spread of droplet-borne respiratory infection, including SARS (<http://isocapnia.com/SARS.htm>). Throughout exhalation, both the nonrebreathing mask and the Venturi-type mask channeled the exhaled gas through the side vents, forming a plume of exhaled gas (marked here by the previously inhaled aerosol) that was directed to the side of the patient. This potentially infectious plume could be directed toward caregivers, visitors, and other patients at face level. The extent of the plume might be greater with oxygen flows or when expiratory flows are increased by coughing, sneezing, or hyperventilation.

Does this model accurately reflect the droplet spread associated with respiratory infections such as SARS? The plumes visible in the figures are composed of the previously inhaled mist that marks the distribution of exhaled gas. We assumed that endogenously produced droplets would be within the distribution of the exhaled gas. The spread of the exhaled gas may be greater than shown, as evaporation and reduction in density of the droplets at the margin of the plume may limit their effectiveness as markers. On the other hand, the visualized cloud does mark the minimum distribution of gas that originated in the lung.

In the mask without side vents, all exhaled gas traverses a manifold containing three valves and exits through a single port. Placing a bacterial/viral filter on this port may provide effective respiratory isolation during oxygen administration to spontaneously breathing patients.

The current recommendations for the management of SARS patients acknowledge the importance of the isolation of exhaled gas to prevent the release of infected droplets into the atmosphere.[@bib5] This can be accomplished with N95 or equivalent masks in spontaneously ventilating patients who do not require oxygen supplementation, and by the placement of bacterial/viral hydrophobic filters on the end of the endotracheal tube and/or the exhalation port of the self-inflating bag or breathing circuit in ventilated patients. However, when oxygen supplementation is required for spontaneously breathing patients, guidelines often condone open oxygen delivery systems that do not retain respiratory droplets.[@bib6] In light of reports of SARS patients infecting other patients and health-care workers during the preintubation phase of their treatment, despite the use of protective equipment by health-care workers, we think that additional measures should be considered.[@bib3] The administration of oxygen using the delivery systems described in this article may further reduce the risk of the nosocomial transmission of respiratory infections such as SARS.
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